Trial Profile
A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Navtemadlin (Primary) ; Danazol; Hydroxycarbamide; Lenalidomide; Peginterferon alfa-2a; Prednisone
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Registrational; Therapeutic Use
- Acronyms BOREAS
- Sponsors Kartos Therapeutics
- 15 Jun 2023 Results (at data cutoff 06Jan 2023, n=113 ) evaluating correlations between biomarkers of disease burden and survival outcomes (progression-free survival[PFS] and OS) , presented at the 28th Congress of the European Haematology Association
- 14 Dec 2021 Primary endpoint has been met. ((Part A Only) Spleen Volume Reduction (SVR))
- 14 Dec 2021 Results assessing correlations between changes in biomarkers of disease burden presented at the 63rd American Society of Hematology Annual Meeting and Exposition